期刊文献+

HPLC-MS测定人血浆中多沙唑嗪及其在健康人体药动学研究中的应用 被引量:4

HPLC-MS determination of doxazosin in the human plasma and its pharmacokinetics
下载PDF
导出
摘要 目的:建立人血浆中多沙唑嗪的高效液相色谱-质谱测定方法,用于研究甲磺酸多沙唑嗪片的健康人体药动学。方法:血浆样品0.25 mL,用正己烷-叔丁基甲醚萃取,以20 mmol·L^(-1)醋酸铵溶液(pH 4.28)-甲醇-乙腈(55:10:35)为流动相,用 Thermo C_(18)柱(150 mm×2.1 mm,5μm)分离,采用高效液相色谱-质谱电喷雾电离法,选择离子监测(SIM)。测定12名健康男性志愿者单剂量口服4 mg 甲磺酸多沙唑嗪片后的血药浓度经时过程。由 DAS2.0药学与统计程序处理计算药动学参数。结果:多沙唑嗪的线性范围为0.5~100 ng·mL^(-1),平均回收率为98.3%,日内 RSD≤8.4%,日间 RSD≤10.5%。结论:分析方法准确、灵敏度高,适用于多沙唑嗪口服制剂的药动学研究。 Objective:To determine doxazosin in human plasma by HPLC -MS method, and to study its pharmacokinetic in healthy volunteers. Methods: Doxazosin concentration in plasma was determined by HPLC - MS. Doxazosin was extracted from plasma with liquid -liquid extraction, and then separated on a Thermo C 18 column( 150 mm × 2. 1 mm ,5 μm). The mobile phase consisted of 20 mmol · L^-1ammonium acetate( pH 4. 28 ) -methanol- acetonitrile(55: 10: 35 ) ;the selected ion was determined by ESI ^+ ;The pharmacokinetic parameters were obtained with the help of DAS2. 0 System. Results:The calibration curve was linear within the range of 0. 5 - 100 ng · mL^-1 (r = 0. 9988 ) ,the recovery was 98.3% ,the RSDs of intra - and inter -day were less than 8.4% and 10. 5%. Conclusion:The method is rapid and sensitive. Pharmacokinetic parameters are consistent with the literature report.
出处 《药物分析杂志》 CAS CSCD 北大核心 2007年第9期1357-1360,共4页 Chinese Journal of Pharmaceutical Analysis
关键词 多沙唑嗪 血浆药物浓度 药动学 高效液相色谱-质谱 doxazosin plasma concentration pharmacokinetics HPLC - MS
  • 相关文献

参考文献5

  • 1卢竞前,曹晶茗.多沙唑嗪应用于心血管病的研究进展[J].现代中西医结合杂志,2005,14(9):1242-1244. 被引量:5
  • 2孙颖浩,刘毅,王林辉,顾正勤,邱镇,高旭.多沙唑嗪对前列腺癌DU-145细胞生长的影响及机理研究[J].中华泌尿外科杂志,2005,26(5):302-304. 被引量:3
  • 3Sripalakit P, Nermhom P, Saraphanchotiwitthaya A. Improvement of doxazosin determination in human plasma using high - performance liquid chromatography with fluorescence detection. J Chromatogr Sci, 2005,43 (2) :63
  • 4LISen(李森).Quantification of doxazosin mesylate by DPP(差示脉冲极谱法测定片剂中的多沙唑嗪)[J].国外医学:药学分册,1998,25(1):64-64.
  • 5Sripalakit P, Nermhom P, Mapbanta S, et al. Bioequivalence evaluation of two formulations of doxazosin tablet in healthy thai male volunteers. Drug Dev Ind Pharm,2005,31 (10) :1035

二级参考文献27

  • 1Berges RR, Vucanovic J, Epstein JI, et al. Implication of cell cycle changes during the progression of human prostate cancer. Clin Cancer Res,1995,1:473-480.
  • 2Bruckheimer EM, Kyprianou N. Apoptosis in prostate carcinogenesis:a growth regulator and a therapeutic target: a review. Cell Tissue Res,2000,301:153-162.
  • 3Yang G,Timme TL,Park S-H, et al. Transforming growth factor-β1 induced prostate reconstitutions: induction of prostate apoptosis by doxazosin. J Urol, 1997,33:157-163.
  • 4Chon J, Borkowski A, Partin AW, et al. αl-adrenoceptor antagonist terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patient with benign prostatic hyperplasia. J Urol,1999,161:2002-2007.
  • 5Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by α1-adrenoceptor antagonist doxazosin and terazosin via induction of apoptosis. Cancer Res,2000,60:4550-4555.
  • 6Wrana JL, Attisano L, Wieser R, et al. Mechanism of activation of the TGF- beta receptor. Nature, 1994,37:341-352.
  • 7Kassen A,Sutkowski DM,Ahn HJ,et al. Stromal cells of human prostate: initial isolation and characterization. Prostate, 1996,28:89-97.
  • 8Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the antihypertensive and lipid-Lowering treatment to prevent heart attack Trial (ALLHAT)[J]. Hypertension,2003,42(3):2392-46.
  • 9Wilson TA,Foxall TL,Nicolosi RJ,et al. Doxazosin,an alpha-1 antagonist prevents further progression of the advanced atherosclerotic lesion in hypercholesterolemic hamsters[J]. Metabolism,2003,52(10):1240-1245.
  • 10Kinoshita M,Shimazu N,Fujita M,et al. Doxazosin,an alpha1-adrenergic antihypertensive agent,decreases serum oxidized LDL[J].Am J Hypertens,2001,14(3):267-270.

共引文献6

同被引文献42

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部